Search

Pancreatic ductal adenocarcinoma (PDA) tumor cells are deprived of oxygen and nutrients and therefore must adapt their metabolism to ensure proliferation. In some physiological states, cells rely on ketone bodies to satisfy their metabolic needs, especially during nutrient stress. Here, we show that PDA cells can activate ketone body metabolism and that β‐hydroxybutyrate (βOHB) is an alternative cell‐intrinsic or systemic fuel that can promote PDA growth and progression. PDA cells activate enzymes required for ketogenesis, utilizing various nutrients as carbon sources for ketone body formation. By assessing metabolic gene expression from spontaneously arising PDA tumors in mice, we find HMG‐CoA lyase (HMGCL), involved in ketogenesis, to be among the most deregulated metabolic enzymes in PDA compared to normal pancreas. In vitro depletion of HMGCL impedes migration, tumor cell invasiveness, and anchorage‐independent tumor sphere compaction. Moreover, disrupting HMGCL drastically decreases PDA tumor growth in vivo, while βOHB stimulates metastatic dissemination to the liver. These findings suggest that βOHB increases PDA aggressiveness and identify HMGCL and ketogenesis as metabolic targets for limiting PDA progression. Synopsis: The molecular mechanisms underlying metabolic flexibility of solid tumor cells exposed to oxygen deprivation remain poorly understood. This study identifies the ketogenic enzyme HMG‐CoA lyase (HMGCL) and its derivative β‐hydroxybutyrate (βOHB) as essential drivers of pancreatic cancer, highlighting ketone body metabolism as a regulatory nexus in metastasis. Systemic βOHB is metabolized by pancreatic adenocarcinoma (PDA) cells, fueling the TCA cycle.HMGCL and βOHB promote PDA tumor aggressiveness and metastatic dissemination.Ketone body metabolic enzymes are upregulated in PDA.PDA cells de novo generate ketone bodies from various carbon sources.Depletion of HMGCL limits oncogenic properties of pancreatic tumor cells in vivo, which is rescued by exogenous βOHB. [ABSTRACT FROM AUTHOR]

The Hippo pathway and its nuclear effector Yap regulate organ size and cancer formation. While many modulators of Hippo activity have been identified, little is known about the Yap target genes that mediate these growth effects. Here, we show that yap−/− mutant zebrafish exhibit defects in hepatic progenitor potential and liver growth due to impaired glucose transport and nucleotide biosynthesis. Transcriptomic and metabolomic analyses reveal that Yap regulates expression of glucose transporter glut1, causing decreased glucose uptake and use for nucleotide biosynthesis in yap−/− mutants, and impaired glucose tolerance in adults. Nucleotide supplementation improves Yap deficiency phenotypes, indicating functional importance of glucose‐fueled nucleotide biosynthesis. Yap‐regulated glut1 expression and glucose uptake are conserved in mammals, suggesting that stimulation of anabolic glucose metabolism is an evolutionarily conserved mechanism by which the Hippo pathway controls organ growth. Together, our results reveal a central role for Hippo signaling in glucose metabolic homeostasis. Synopsis: The Hippo pathway has emerged as a master regulator of organ size control. Here, genetic models combined with in vivo metabolomic flux analyses identify Yap as a conserved regulator of glucose metabolism, fueling organogenesis but at the same time acting as a gatekeeper of anabolism against energetic stress. Yap is required for optimal liver growth and hepatoblast development in zebrafish.Yap regulates expression of the glucose transporter Glut1 in vivo.Yap‐deficient embryos exhibit decreased glycolytic flux into nucleotide biosynthesis.Metabolic intervention by deoxynucleoside addition rescues the Yap‐deficiency growth phenotype.Regulation of glut1 and glucose uptake by Yap is conserved in mouse hepatocytes. Hippo signaling controls glucose uptake and energy metabolism required for liver homeostasis in zebrafish and mouse. [ABSTRACT FROM AUTHOR]